{"id":"W2943864790","doi":"10.1016/s1470-2045(19)30178-0","title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":86,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Cilag; Genentech; F. Hoffmann-La Roche; Roche; Merck; Amgen","keywords":"Medicine; Clinical endpoint; Ovarian cancer; Carboplatin; Population; Progression-free survival; Internal medicine; Placebo; Oncology; Phases of clinical research; Clinical trial; Gynecology; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005179908,0.0003541996,0.0008686027,0.00004769428,0.0001868584,0.00003039045,0.0002779208,0.0003348969,0.0002546524],"category_scores_gemma":[0.00006694959,0.0002201455,0.000234556,0.0001111806,0.0001232133,0.000008221553,0.00009200764,0.0001104847,0.00001471239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002065594,"about_ca_system_score_gemma":0.0006341971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004796992,"about_ca_topic_score_gemma":0.002153758,"domain_scores_codex":[0.9981265,0.0001373795,0.0004320348,0.000618298,0.0001216848,0.0005640927],"domain_scores_gemma":[0.9986362,0.0002787605,0.000279805,0.0005843895,0.00009431692,0.0001265653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9424542,0.0003371629,0.00007201877,0.0000506262,0.0005009715,0.000008769316,0.0002637138,0.0003590937,0.02099363,0.0003576078,0.002078404,0.0325238],"study_design_scores_gemma":[0.6344749,0.007455151,0.00001909328,0.0000179146,0.0001977575,0.00002477623,0.0001034828,0.0001945885,0.01344778,0.00005164873,0.3437537,0.0002591943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.983933,0.004071753,0.000387113,0.003140343,0.0009388727,0.0052897,0.0002546434,0.00002896505,0.001955558],"genre_scores_gemma":[0.9766869,0.006331683,0.0004873208,0.001331489,0.003342299,0.003919995,0.000241017,0.00006789528,0.007591432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3416753,"threshold_uncertainty_score":0.8977273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08349518990222415,"score_gpt":0.400998555831424,"score_spread":0.3175033659291999,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}